MT2012-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- up to 50 years old - diagnosis of immunodeficiency or histiocytic disorder - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- pregnant or breastfeeding - active, uncontrolled infection and/or HIV positive - acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy

Conditions & Interventions

Interventions:
Drug: Alemtuzumab 0.2 mg, Drug: Alemtuzumab 0.3 mg, Drug: Busulfan, Drug: Busulfan, Drug: Cyclophosphamide, Drug: Fludarabine phosphate 30 mg, Drug: Fludarabine phosphate 40 mg, Drug: MESNA, Drug: Melphalan, Biological: Stem Cell Transplantation
Conditions:
Immune Diseases, Rare Diseases
Keywords:
Clinics and Surgery Center (CSC), Allogeneic Hematopoietic Stem Cell Transplant, Primary Immune Deficiencies

More Information

Description: The primary purpose of this study is to record outcomes and patient characteristics in the Cancer Center's and BMT databases for patients who are undergoing an allogeneic (donor) hematopoietic stem cell transplant. The data will be analyzed for transplant "milestones" such as time to blood count recovery (engraftment) and how patients are doing at 3 months and 6 months after the transplant. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.
Study Contact: Christen Ebens - ebens012@umn.edu
Principal Investigator: Christen Ebens
Phase: NA
IRB Number: 1207M17321